Modulation of histone lactylation and pharmacological inhibition of STAT3 can restore immune sensitivity in B7-H3-mediated resistance, promisingly highlighting potential of combining targeted or epigenetic therapies with immunotherapeutic approaches to overcome tumor immune evasion [229,230]. The gene discussed is STAT3; the disease is neoplasm.